Creative Planning Sells 10,000 Shares of Halozyme Therapeutics, Inc. (HALO)

Creative Planning reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 63,792 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the quarter. Creative Planning’s holdings in Halozyme Therapeutics were worth $1,159,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in shares of Halozyme Therapeutics by 5.7% in the 2nd quarter. BlackRock Inc. now owns 12,242,431 shares of the biopharmaceutical company’s stock worth $206,530,000 after buying an additional 659,763 shares during the last quarter. Iridian Asset Management LLC CT lifted its position in shares of Halozyme Therapeutics by 0.8% in the 2nd quarter. Iridian Asset Management LLC CT now owns 8,260,476 shares of the biopharmaceutical company’s stock worth $139,354,000 after buying an additional 68,098 shares during the last quarter. Northern Trust Corp lifted its position in shares of Halozyme Therapeutics by 11.1% in the 2nd quarter. Northern Trust Corp now owns 1,841,060 shares of the biopharmaceutical company’s stock worth $31,059,000 after buying an additional 183,480 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in shares of Halozyme Therapeutics by 0.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,709,020 shares of the biopharmaceutical company’s stock worth $28,831,000 after buying an additional 11,260 shares during the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $21,690,000. Institutional investors own 84.68% of the company’s stock.

Several brokerages recently weighed in on HALO. BidaskClub upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. Piper Jaffray Companies reiterated a “neutral” rating on shares of Halozyme Therapeutics in a research report on Friday, October 19th. BMO Capital Markets lifted their price objective on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the company a “market perform” rating in a research report on Wednesday, August 8th. Cantor Fitzgerald began coverage on shares of Halozyme Therapeutics in a research report on Wednesday, August 22nd. They issued an “overweight” rating and a $27.00 price objective on the stock. Finally, ValuEngine downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 19th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $20.78.

Shares of NASDAQ:HALO opened at $16.03 on Friday. The stock has a market capitalization of $2.31 billion, a P/E ratio of 35.62 and a beta of 1.88. Halozyme Therapeutics, Inc. has a fifty-two week low of $14.33 and a fifty-two week high of $21.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.43 and a current ratio of 3.49.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.06. The firm had revenue of $35.20 million for the quarter, compared to the consensus estimate of $31.49 million. Halozyme Therapeutics had a net margin of 23.88% and a return on equity of 38.10%. On average, research analysts expect that Halozyme Therapeutics, Inc. will post -0.81 earnings per share for the current fiscal year.

In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 146,718 shares of the firm’s stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $17.52, for a total transaction of $2,570,499.36. Following the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at approximately $62,413,037.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Randal J. Kirk sold 490,072 shares of the firm’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $17.30, for a total transaction of $8,478,245.60. Following the transaction, the insider now directly owns 3,562,388 shares in the company, valued at approximately $61,629,312.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,513,468 shares of company stock worth $61,759,078. 16.80% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

See Also: Hedge Funds Explained

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply